Strides Arcolab’s arm gets USFDA nod for Oxaliplatin injection

Strides Arcolab’s subsidiary - Onco Therapies has got a tentative approval of US Food and Drug Administration (USFDA) for generic Oxaliplatin injection. The tentative approval is for 50 mg and 100 mg strengths of the injection.

Oxaliplatin is a platinum-based complex that is prescribed in chemotherapy treatment of colorectal cancer and marketed by French pharmaceutical company Sanofi-Aventis under the brand name Eloxatin.

Recently, Onco Therapies had received USFDA approval for Carboplatin Injection 10 mg/mL packaged in 50mg/mL, 150mg/mL, 450 mg/45 mL and 600 mg/60 mL Multi-dose vials.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.